Fulton Bank N.A. increased its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) by 3.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,754 shares of the pharmaceutical company’s stock after buying an additional 2,083 shares during the period. Fulton Bank N.A.’s holdings in GlaxoSmithKline PLC were worth $3,094,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in GSK. Alta Capital Management LLC raised its position in shares of GlaxoSmithKline PLC by 2.2% in the second quarter. Alta Capital Management LLC now owns 26,886 shares of the pharmaceutical company’s stock valued at $1,159,000 after buying an additional 568 shares in the last quarter. City Holding Co. raised its position in shares of GlaxoSmithKline PLC by 12.7% in the second quarter. City Holding Co. now owns 45,342 shares of the pharmaceutical company’s stock worth $1,955,000 after buying an additional 5,094 shares during the period. Beacon Financial Group raised its position in shares of GlaxoSmithKline PLC by 5.8% in the second quarter. Beacon Financial Group now owns 169,223 shares of the pharmaceutical company’s stock worth $7,321,000 after buying an additional 9,206 shares during the period. Trust Co raised its position in shares of GlaxoSmithKline PLC by 2.4% in the first quarter. Trust Co now owns 23,673 shares of the pharmaceutical company’s stock worth $998,000 after buying an additional 547 shares during the period. Finally, Catawba Capital Management VA raised its position in shares of GlaxoSmithKline PLC by 8.6% in the second quarter. Catawba Capital Management VA now owns 20,248 shares of the pharmaceutical company’s stock worth $873,000 after buying an additional 1,600 shares during the period. Institutional investors own 8.96% of the company’s stock.
GlaxoSmithKline PLC (NYSE GSK) traded down 0.28% during mid-day trading on Friday, reaching $38.79. The company’s stock had a trading volume of 2,329,225 shares. The firm has a 50-day moving average of $41.84 and a 200 day moving average of $41.84. The firm has a market capitalization of $94.80 billion, a price-to-earnings ratio of 37.51 and a beta of 1.03. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.59.
GlaxoSmithKline PLC (NYSE:GSK) last announced its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The firm had revenue of $9.36 billion during the quarter, compared to the consensus estimate of $9.52 billion. Equities analysts expect that GlaxoSmithKline PLC will post $2.85 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be paid a dividend of $0.491 per share. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend is Wednesday, August 9th. This represents a $1.96 annualized dividend and a yield of 5.06%. GlaxoSmithKline PLC’s dividend payout ratio is presently 197.00%.
TRADEMARK VIOLATION NOTICE: This article was first reported by BNB Daily and is the property of of BNB Daily. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.baseball-news-blog.com/2017/08/13/fulton-bank-n-a-acquires-2083-shares-of-glaxosmithkline-plc-gsk-updated-updated-updated.html.
GSK has been the topic of a number of research reports. Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “hold” rating to a “sell” rating in a research report on Monday, April 17th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Tuesday, April 25th. TheStreet raised GlaxoSmithKline PLC from a “c” rating to a “b” rating in a report on Friday, May 19th. Berenberg Bank raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a report on Friday, May 26th. Finally, ValuEngine downgraded GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. GlaxoSmithKline PLC currently has an average rating of “Hold” and a consensus price target of $44.67.
GlaxoSmithKline PLC Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.